216 related articles for article (PubMed ID: 10492502)
1. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity.
Luque CA; Rey JA
Ann Pharmacother; 1999 Sep; 33(9):968-78. PubMed ID: 10492502
[TBL] [Abstract][Full Text] [Related]
2. A benefit-risk assessment of sibutramine in the management of obesity.
Nisoli E; Carruba MO
Drug Saf; 2003; 26(14):1027-48. PubMed ID: 14583064
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
4. Sibutramine and the management of obesity.
Poston WS; Foreyt JP
Expert Opin Pharmacother; 2004 Mar; 5(3):633-42. PubMed ID: 15013931
[TBL] [Abstract][Full Text] [Related]
5. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study.
Milano W; Petrella C; Casella A; Capasso A; Carrino S; Milano L
Adv Ther; 2005; 22(1):25-31. PubMed ID: 15943219
[TBL] [Abstract][Full Text] [Related]
6. Sibutramine. A review of its contribution to the management of obesity.
McNeely W; Goa KL
Drugs; 1998 Dec; 56(6):1093-124. PubMed ID: 9878996
[TBL] [Abstract][Full Text] [Related]
7. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.
Apfelbaum M; Vague P; Ziegler O; Hanotin C; Thomas F; Leutenegger E
Am J Med; 1999 Feb; 106(2):179-84. PubMed ID: 10230747
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
[TBL] [Abstract][Full Text] [Related]
9. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
Smith IG; Goulder MA;
J Fam Pract; 2001 Jun; 50(6):505-12. PubMed ID: 11407998
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
[TBL] [Abstract][Full Text] [Related]
11. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity.
Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
Int J Obes Relat Metab Disord; 2000 Feb; 24(2):144-50. PubMed ID: 10702763
[TBL] [Abstract][Full Text] [Related]
12. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
[TBL] [Abstract][Full Text] [Related]
13. Sibutramine: new preparation. Slight weight loss; but also a slight rise in blood pressure ..
Prescrire Int; 2001 Oct; 10(55):140-5. PubMed ID: 11824428
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.
McMahon FG; Fujioka K; Singh BN; Mendel CM; Rowe E; Rolston K; Johnson F; Mooradian AD
Arch Intern Med; 2000 Jul; 160(14):2185-91. PubMed ID: 10904462
[TBL] [Abstract][Full Text] [Related]
15. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
Int J Obes Relat Metab Disord; 2001 May; 25(5):741-7. PubMed ID: 11360159
[TBL] [Abstract][Full Text] [Related]
16. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
[TBL] [Abstract][Full Text] [Related]
17. The discovery and status of sibutramine as an anti-obesity drug.
Luque CA; Rey JA
Eur J Pharmacol; 2002 Apr; 440(2-3):119-28. PubMed ID: 12007530
[TBL] [Abstract][Full Text] [Related]
18. Sibutramine lost and found.
Bosello O; Carruba MO; Ferrannini E; Rotella CM
Eat Weight Disord; 2002 Sep; 7(3):161-7. PubMed ID: 12452247
[TBL] [Abstract][Full Text] [Related]
19. A comparison of sibutramine and dexfenfluramine in the treatment of obesity.
Hanotin C; Thomas F; Jones SP; Leutenegger E; Drouin P
Obes Res; 1998 Jul; 6(4):285-91. PubMed ID: 9688105
[TBL] [Abstract][Full Text] [Related]
20. Sibutramine produces dose-related weight loss.
Bray GA; Blackburn GL; Ferguson JM; Greenway FL; Jain AK; Mendel CM; Mendels J; Ryan DH; Schwartz SL; Scheinbaum ML; Seaton TB
Obes Res; 1999 Mar; 7(2):189-98. PubMed ID: 10102256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
